The preventive effect of tamsulosin on voiding dysfunction after prostate biopsy: a prospective, open-label, observational study

Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS (2013) Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat Off J Korean Cancer Assoc 45(1):1–14

Hodge KK, McNeal JE, Terris MK, Stamey TA (1989) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142(1):71–74; discussion 4–5

Hodge KK, McNeal JE, Stamey TA (1989) Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142(1):66–70

Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS (2011) Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 77(4):910–914

Zisman A, Leibovici D, Kleinmann J, Cooper A, Siegel Y, Lindner A (2001) The impact of prostate biopsy on patient well-being: a prospective study of voiding impairment. J Urol 166(6):2242–2246

Berger AP, Gozzi C, Steiner H, Frauscher F, Varkarakis J, Rogatsch H, et al. (2004) Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol 171(4):1478–1480; discussion 80–81

Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M et al (2001) Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 166(3):856–860

Aus G, Ahlgren G, Bergdahl S, Hugosson J (1996) Infection after transrectal core biopsies of the prostate–risk factors and antibiotic prophylaxis. Br J Urol 77(6):851–855

Rietbergen JB, Kruger AE, Kranse R, Schroder FH (1997) Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 49(6):875–880

Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH (2002) Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 60(5):826–830

Mkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL (2002) Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology 60(5):846–850

Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL (2000) Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 163(1):158–162

Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R et al (2013) Systematic review of complications of prostate biopsy. Eur Urol 64(6):876–892

Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M (2001) Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 166(4):1358–1363

O’Leary MP (2001) Tamsulosin: current clinical experience. Urology 58(6 Suppl 1):42–48; discussion 8

Bozlu M, Ulusoy E, Doruk E, Cayan S, Canpolat B, Schellhammer PF et al (2003) Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity? Urology 62(6):1050–1053